Loading...
SEEL.Q logo

Seelos Therapeutics, Inc.OTCPK:SEEL.Q Stock Report

Market Cap US$136.0
Share Price
n/a
1Y9,900.0%
7D0%
1D9,900.0%
Portfolio Value
​
View

Seelos Therapeutics, Inc.

OTCPK:SEEL.Q Stock Report

Market Cap: US$136.0

Seelos Therapeutics (SEEL.Q) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. More details

SEEL.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($136)

Latest financial reports are more than a year old


SEEL.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,212 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
497,212 investors already sharing narratives
View all narratives

Seelos Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Seelos Therapeutics
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.01
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change9,900.00%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 04

Seelos: Data This Year Is Critical

Summary Seelos has an interesting drug platform. They are planning to release critical data this year. Their cash position was not good, but has been recently bolstered with a market offering. I covered Seelos (SEEL) twice before, and I see from my notes that I also had a detailed communication with company management in order to better understand the company. Despite my initial interest, my plan to take a pilot position in the company did not materialize. This has nothing to do with Seelos specifically, and more to do with the terrible market conditions we saw in the early months of 2022. However, that turned out to be a good thing, because SEEL has mostly traded down in 2022, with a recovery obtaining just in the last couple of months. Seelos makes therapeutic medicines using psychedelic drugs. It also has gene therapy programs. The company has two assets in human trials, SLS-002 targeting ASIB-MDD or acute suicidal ideation and behavior in major depressive disorder, and SLS-005 targeting Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. This last one has a pivotal phase 2/3 trial ongoing since Q1 2022, and also a second pivotal trial in Spinocerebellar Ataxia ((SCA)) which commenced in Q2. Nearest data drop is, however, from SLS-002, which will have a proof of concept study's part 2 data in 2H. An important thing that transpired in July was that the FDA agreed to consider the part 2 study - a large, double-blind, randomized trial - as registrational. That means, the company should be able to submit an NDA in the early months of 2023, and get a PDUFA by the end of 2023. This immediately enhances the value of SEEL. The part 1 data for SLS-02 was quite strong. From the company presentation: All doses judged to be safe and well tolerated with no new or unique safety signals No serious adverse events (SAEs) and all AEs were transient and clinically manageable Expected transient increase in Clinician Administered Dissociative State Scale (CADSS) scores at the higher dose groups (75 mg and 90mg) correlated with Cmax (~40 mins), that resolved with mean values < 4 points at one hour All subjects had a CADSS score < 4 points at two hours Expected mild and transient increase in blood pressure from 30 to 90 minutes post dose, all mean values remained within normal limits, and resolved without intervention Across 4 scales used to measure suicidal ideation, SLS-02 showed strong clinical improvements, as follows: BASELINE (n=17) DAY 1 (n=17) DAY 16 (n=14) MADRS (0-60 scale, ≤12 is remission) 39.4 14.5 7.4 CGIS-SI/B (1-5 scale, 1=not at all, 5=extremely suicidal) 3.8 1.6 1.1 S-STS (0-52 scale, higher score equated to higher suicidality) 22.4 1.7 0.0 PGIS-SI/B (1-5 scale, 1=not present, 5=extremely severe) 3.5 1.6 1.0 MADRS Item-10 (0-6 scale, ≤3 is defined as a response) 5.2 0.8 0.1
Seeking Alpha • Aug 24

Seelos wins Parkinson’s research grant for gene therapy program

Clinical-stage biopharma, Seelos Therapeutics, Inc. (NASDAQ:SEEL), announced Wednesday that the Michael J. Fox Foundation, the world's largest nonprofit funder of Parkinson's research, has selected the company for a grant to advance its lead program for gene therapy candidate SLS-004. With no currently approved therapies to prevent the disease or end its progression, PD remains the world's second most prevalent neurodegenerative disorder. SLS-004 uses CRISPR-dCas9 gene editing to modulate the expression of the SNCA gene, which is thought to be a very significant genetic risk factor for Parkinson's disease (PD). "The selection of SLS-004 to receive grant funding from The Michael J. Fox Foundation is a strong validation of our program and should significantly raise the profile of our program," SEEL's Chief Executive Raj Mehra remarked. Read: In 2021, SEEL announced data for SLS-004 using a rodent model.
Seeking Alpha • Dec 22

Seelos: FDA Action Makes It Highly Attractive

Seelos received communication from the FDA that its part 2 study will be considered registrational. This derisks the company considerably, although the only efficacy data we have so far is from an open label trial. I am considering a pilot position in this stock.
Seeking Alpha • Oct 01

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

Buying volume has increased a lot in recent sessions. The company's SLS-002 offering has been demonstrating good results. Investors are becoming attracted due to the high unmet need in this area. We are looking at selling puts here which is the percentage play in SEEL at present.

Shareholder Returns

SEEL.QUS PharmaceuticalsUS Market
7D0%1.4%1.6%
1Y9,900.0%48.6%18.6%

Return vs Industry: SEEL.Q exceeded the US Pharmaceuticals industry which returned 48.6% over the past year.

Return vs Market: SEEL.Q exceeded the US Market which returned 18.6% over the past year.

Price Volatility

Is SEEL.Q's price volatile compared to industry and market?
SEEL.Q volatility
SEEL.Q Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: SEEL.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SEEL.Q's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aRaj Mehraseelostherapeutics.com

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Seelos Therapeutics, Inc. Fundamentals Summary

How do Seelos Therapeutics's earnings and revenue compare to its market cap?
SEEL.Q fundamental statistics
Market capUS$136.00
Earnings (TTM)US$4.09m
Revenue (TTM)US$2.01m
0.0x
P/E Ratio
0.0x
P/S Ratio

Is SEEL.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SEEL.Q income statement (TTM)
RevenueUS$2.01m
Cost of RevenueUS$20.45m
Gross Profit-US$18.43m
Other Expenses-US$22.53m
EarningsUS$4.09m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did SEEL.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 13:41
End of Day Share Price 2026/06/01 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seelos Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG